JPMorgan Chase & Co. Raises Establishment Labs (NASDAQ:ESTA) Price Target to $71.00

Establishment Labs (NASDAQ:ESTA) had its price target increased by equities researchers at JPMorgan Chase & Co. from $45.00 to $71.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 9.23% from the stock’s previous close.

Other equities analysts also recently issued reports about the company. Wall Street Zen raised Establishment Labs from a “sell” rating to a “hold” rating in a research note on Sunday, October 19th. Canaccord Genuity Group upped their price objective on Establishment Labs from $60.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday. Mizuho raised their target price on Establishment Labs from $70.00 to $85.00 and gave the company an “outperform” rating in a report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Establishment Labs in a research note on Wednesday, October 8th. Finally, Citigroup reiterated a “neutral” rating on shares of Establishment Labs in a report on Tuesday, October 7th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $66.71.

Establishment Labs Stock Up 0.1%

ESTA stock opened at $65.00 on Thursday. The stock has a market capitalization of $1.88 billion, a PE ratio of -22.89 and a beta of 0.98. The company has a fifty day moving average of $44.13 and a 200-day moving average of $40.41. The company has a debt-to-equity ratio of 9.71, a quick ratio of 1.67 and a current ratio of 2.84. Establishment Labs has a one year low of $26.56 and a one year high of $65.45.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.16. The business had revenue of $53.78 million for the quarter, compared to analyst estimates of $52.28 million. Establishment Labs had a negative net margin of 43.45% and a negative return on equity of 201.85%. The business’s revenue was up 33.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.59) earnings per share. Establishment Labs has set its FY 2025 guidance at EPS. As a group, analysts expect that Establishment Labs will post -2.41 EPS for the current year.

Institutional Investors Weigh In On Establishment Labs

Several institutional investors and hedge funds have recently made changes to their positions in the business. State of Wyoming acquired a new stake in Establishment Labs in the 3rd quarter valued at about $71,000. ANTIPODES PARTNERS Ltd purchased a new stake in shares of Establishment Labs in the first quarter valued at about $81,000. Osaic Holdings Inc. lifted its holdings in shares of Establishment Labs by 900.0% in the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after purchasing an additional 1,800 shares in the last quarter. CWM LLC grew its position in shares of Establishment Labs by 45.9% in the second quarter. CWM LLC now owns 2,182 shares of the company’s stock valued at $93,000 after purchasing an additional 686 shares during the last quarter. Finally, Brian Low Financial Group LLC purchased a new position in shares of Establishment Labs during the 3rd quarter worth approximately $223,000. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.